Navigation Links
Valeant to Acquire Polish Dermatology Company

ALISO VIEJO, Calif., May 8 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) announced that it has acquired EMO-FARM Ltd., a privately held company located in Poland for approximately $28 million. The transaction expands the base for Valeant in Poland into multiple therapeutic categories. EMO-FARM has a strong expertise in topical products and brings with it a portfolio of currently marketed products and additional products under registration. As part of the transaction, Valeant will also acquire a state-of-the-art 13,000 square foot manufacturing plant completed earlier this year that specializes in gels, creams and ointments. Current annualized revenues are approximately $12 million.

"The acquisition of EMO-FARM is consistent with our business plan strategy," stated J. Michael Pearson, chairman and chief executive officer. "We now have a platform from which we can launch various topical products including our dermatology pipeline and become a premier dermatology company in the countries in which we operate The combination of an established portfolio of products, an anti-infective topical compound we plan to launch in 2010, and a cGMP-ready plant that equips us with new manufacturing capabilities, provides us with a solid dermatology opportunity in Poland, and eventually, throughout Central Europe."

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at


This press release may contain forward-looking statements, including, but not limited to, statements regarding the future growth in Valeant's European dermatology franchise, the impact of the EMO-FARM Ltd. acquisition on Valeant's business, the timing and potential success of registration and the approval of product candidates. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to our ability to successfully integrate the EMO-FARM assets, risks and uncertainties relating to the clinical development of product candidates, regulatory approval processes, the potential that competitors may bring to market products or treatments that are more commercially attractive than existing or future EMO-FARM products, and other risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the SEC, which factors are incorporated herein by reference. These risks are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements and undue reliance should not be placed on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Laurie W. Little
    Valeant Pharmaceuticals


SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
2. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
3. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
4. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
9. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
10. JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares
11. Teikoku Pharma USA Acquires Travanti Pharma Inc.
Post Your Comments:
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: